Loading clinical trials...

COMPLETEDPHASE1

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

A Phase I, Single Centre, Open, Randomised, Parallel Study to Evaluate the Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine in Healthy Subject

NCT00900237•Bial - Portela C S.A.

View on ClinicalTrials.gov

Summary

This purpose of this study is to measure the concentrations of two anti-epileptic drugs (Eslicarbazepine acetate and oxcarbazepine) and their metabolites in the cerebrospinal fluid and blood plasma of healthy subjects and also to assess how these drugs are tolerated.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy subjects
•Aged 18-55 years
•Body mass index (18.5-29 kg/m3)

Locations (1)

SGS LSS Clinical Pharmacology Unit Antwerpen

Antwerp, Belgium

Key Dates

Start Date

November 1, 2008

Primary Completion Date

December 1, 2008

Completion Date

February 1, 2009

Last Updated

December 19, 2014

Enrollment

ACTUAL participants

Conditions

Partial Epilepsy

Interventions

Eslicarbazepine acetate

DRUG

Oxcarbazepine

DRUG

Surgery as a Treatment for Medically Intractable Epilepsy

NCT01273129

EpilepsyEpilepsy, Temporal Lobe+1 more

View study

COMPLETEDPHASE1

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

NCT04903314

Partial Epilepsy

View study

COMPLETED

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine

Inclusion Criteria

Surgery as a Treatment for Medically Intractable Epilepsy

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

Cenobamate Expanded Access Program (EAP)

PRX-00023 Therapy in Localization-Related Epilepsy

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy